HRP20230282T3 - Monoklonska antitijela protiv klaudina-18 za liječenje raka - Google Patents
Monoklonska antitijela protiv klaudina-18 za liječenje rakaInfo
- Publication number
- HRP20230282T3 HRP20230282T3 HRP20230282TT HRP20230282T HRP20230282T3 HR P20230282 T3 HRP20230282 T3 HR P20230282T3 HR P20230282T T HRP20230282T T HR P20230282TT HR P20230282 T HRP20230282 T HR P20230282T HR P20230282 T3 HRP20230282 T3 HR P20230282T3
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- pharmaceutical preparation
- dsm
- use according
- cells
- Prior art date
Links
- 102000002038 Claudin-18 Human genes 0.000 title claims 3
- 108050009324 Claudin-18 Proteins 0.000 title claims 3
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 11
- 206010027476 Metastases Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 230000009089 cytolysis Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 230000009401 metastasis Effects 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 3
- 230000004540 complement-dependent cytotoxicity Effects 0.000 claims 3
- 230000035755 proliferation Effects 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- 208000000675 Krukenberg Tumor Diseases 0.000 claims 2
- 206010027462 Metastases to ovary Diseases 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000022534 cell killing Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000005764 inhibitory process Effects 0.000 claims 2
- 210000001165 lymph node Anatomy 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010063916 Metastatic gastric cancer Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000009918 complex formation Effects 0.000 claims 1
- 239000013068 control sample Substances 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000012636 effector Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000003622 mature neutrocyte Anatomy 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 208000037819 metastatic cancer Diseases 0.000 claims 1
- 208000011575 metastatic malignant neoplasm Diseases 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 210000005087 mononuclear cell Anatomy 0.000 claims 1
- 210000000822 natural killer cell Anatomy 0.000 claims 1
- -1 radioisotope Substances 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3046—Stomach, Intestines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (18)
1. Postupak za detektiranje metastatskih stanica raka želuca, koji obuhvaća dovođenje u kontakt uzorka dobivenog iz Krukenbergovog tumora ili uzorka dobivenog iz limfnih čvorova, i kontrolnog uzorka, sa antitijelom koje se specifično veže za klaudin-18 spojene varijante 2 (CLD18A2), pod uvjetima koji omogućavaju formiranje kompleksa između antitijela ili njegovog antigen-vezujućeg dijela i CLD18A2, naznačen time, što povećana količina formiranja kompleksa u uzorku ukazuje na metastatske stanice u uzorku.
2. Postupak prema patentnom zahtjevu 1, naznačen time, što metastatske stanice raka predstavljaju stanice Krukenbergovog tumora.
3. Farmaceutski pripravak koji sadrži antitijelo i/ili konjugat koji sadrži navedeno antitijelo povezano sa terapijskim sredstvom i farmaceutski prihvatljiv nosač, za uporabu u postupku za liječenje metastaze raka želuca,
naznačen time, što navedeno antitijelo ima sposobnost vezanja za CLD18A2 i posredovanja u ubijanju stanica koje eksprimiraju CLD18A2 induciranjem lize posredovane citotoksičnosti ovisnom od komplementa (CDC) ili induciranjem lize posredovane staničnom citotoksičnosti ovisnom od antitijela (ADCC) i/ili inhibicijom proliferacije stanica koje eksprimiraju CLD18A2.
4. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 3, naznačen time, što se navedeno antitijelo veže za klaudin-18 spojene varijante 1 (CLD18A1) i CLD18A2.
5. Farmaceutski pripravak za uporabu prema patentnom zahtjevu 3, naznačen time, što se navedeno antitijelo veže za CLD18A2, ali ne i za CLD18A1.
6. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 3-5, naznačen time, što se navedeno ubijanje stanica i/ili inhibicija proliferacije induciraju vezanjem navedenog antitijela za CLD18A2 koji eksprimiraju navedene stanice.
7. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 3-6, naznačen time, što se navedeno ubijanje stanica i/ili inhibicija proliferacije ne induciraju vezanjem navedenog antitijela za CLD18A1 koji eksprimiraju navedene stanice.
8. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 3-7, naznačen time, što navedeno antitijelo ne inducira CDC-posredovanu lizu navedenih stanica.
9. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 3-8, naznačen time, što se navedena ADCC-posredovana liza odvija u prisustvu efektorskih stanica odabranih iz grupe koja se sastoji od monocita, mononuklearnih stanica, NK stanica i PMN stanica.
10. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 3-9, naznačen time, što je navedeno antitijelo monoklonsko, kimerno ili humanizirano antitijelo, ili antigen-vezujući fragment antitijela.
11. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 3-10, naznačen time, što je navedeno antitijelo odabrano iz grupe koja se sastoji od IgG1, IgG2, IgG2a i IgG2b, IgG3, IgG4, IgM, IgA1, IgA2, sekretornog IgA, IgD, i IgE antitijela.
12. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 3-11, naznačen time, što CLD18A2 ima aminokiselinsku sekvencu prema SEQ ID NO: 2.
13. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 4-12, naznačen time, što CLD18A1 ima aminokiselinsku sekvencu prema SEQ ID NO: 8.
14. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 3-13, naznačen time, što je navedeno antitijelo specifično za stanice raka želuca.
15. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 3-14, naznačen time, što se navedeni CLD18A2 eksprimira na površini navedenih stanica.
16. Farmaceutski pripravak koji sadrži antitijelo koje se veže za CLD18A2 i/ili konjugat koji sadrži navedeno antitijelo povezano sa terapijskim sredstvom, i farmaceutski prihvatljiv nosač, za uporabu u postupku za liječenje metastaze raka želuca,
naznačen time, što navedeno antitijelo proizvodi klon deponiran pod pristupnim br. DSM ACC2737, DSM ACC2738, DSM ACC2739, DSM ACC2740, DSM ACC2741, DSM ACC2742, DSM ACC2743, DSM ACC2745, DSM ACC2746, DSM ACC2747, DSM ACC2748, DSM ACC2808, DSM ACC2809 ili DSM ACC2810.
17. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 3-16, naznačen time, što je navedeno terapijsko sredstvo toksin, radioizotop, lijek ili citotoksično sredstvo.
18. Farmaceutski pripravak za uporabu prema bilo kojem od patentnih zahtjeva 3-17, naznačen time, što je navedena metastaza raka želuca metastaza u limfnim čvorovima.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US93209907P | 2007-05-29 | 2007-05-29 | |
| EP07010622A EP1997832A1 (en) | 2007-05-29 | 2007-05-29 | Monoclonal antibodies against Claudin-18 for treatment of cancer |
| EP18168460.6A EP3401334B1 (en) | 2007-05-29 | 2008-05-27 | Monoclonal antibodies against claudin-18 for treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230282T3 true HRP20230282T3 (hr) | 2023-05-12 |
Family
ID=38650052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230282TT HRP20230282T3 (hr) | 2007-05-29 | 2008-05-27 | Monoklonska antitijela protiv klaudina-18 za liječenje raka |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US8425902B2 (hr) |
| EP (4) | EP1997832A1 (hr) |
| JP (3) | JP5816431B2 (hr) |
| KR (3) | KR101693365B1 (hr) |
| CN (2) | CN101687929B (hr) |
| BR (1) | BRPI0811907A2 (hr) |
| CA (1) | CA2687206C (hr) |
| DK (1) | DK3401334T5 (hr) |
| ES (2) | ES2940775T3 (hr) |
| FI (1) | FI3401334T3 (hr) |
| HR (1) | HRP20230282T3 (hr) |
| HU (1) | HUE061795T2 (hr) |
| IL (3) | IL201666A (hr) |
| LT (1) | LT3401334T (hr) |
| MX (1) | MX2009012906A (hr) |
| NZ (1) | NZ581365A (hr) |
| PL (1) | PL3401334T3 (hr) |
| PT (1) | PT3401334T (hr) |
| RS (1) | RS64065B1 (hr) |
| RU (2) | RU2682285C2 (hr) |
| SG (1) | SG183773A1 (hr) |
| SI (1) | SI3401334T1 (hr) |
| WO (1) | WO2008145338A2 (hr) |
| ZA (1) | ZA200907675B (hr) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6358588A (ja) * | 1986-08-29 | 1988-03-14 | Toshiba Corp | バ−コ−ド読取装置 |
| DE10254601A1 (de) | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| DE102004024617A1 (de) * | 2004-05-18 | 2005-12-29 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| US10416162B2 (en) | 2007-12-20 | 2019-09-17 | Monogram Biosciences, Inc. | Her2 diagnostic methods |
| EP2282769A4 (en) | 2008-04-29 | 2012-04-25 | Abbott Lab | DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND ITS USES |
| EP2297209A4 (en) | 2008-06-03 | 2012-08-01 | Abbott Lab | IMMUNOGLOBULINS WITH TWO VARIABLE DOMAINS AND USES THEREOF |
| JP5723769B2 (ja) | 2008-06-03 | 2015-05-27 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリン及びその使用 |
| EP2321422A4 (en) | 2008-07-08 | 2013-06-19 | Abbvie Inc | PROSTAGLANDINE E2 VARIABLE DOUBLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF |
| EP2438442B1 (en) | 2008-12-01 | 2017-08-09 | Laboratory Corporation of America Holdings | Methods and assays for measuring p95 and/or p95 complexes in a sample and antibodies specific for p95 |
| SG172983A1 (en) * | 2009-01-15 | 2011-08-29 | Lab Corp America Holdings | Methods of determining patient response by measurement of her-3 |
| CN107028969A (zh) | 2009-02-20 | 2017-08-11 | 加尼梅德药物公司 | 用于癌症诊断和治疗的方法和组合物 |
| US20110008766A1 (en) * | 2009-05-01 | 2011-01-13 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| SG178602A1 (en) | 2009-09-01 | 2012-04-27 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| WO2011047262A2 (en) | 2009-10-15 | 2011-04-21 | Abbott Laboratories | Dual variable domain immunoglobulins and uses thereof |
| UY32979A (es) | 2009-10-28 | 2011-02-28 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
| NZ734307A (en) | 2009-11-11 | 2020-05-29 | Ganymed Pharmaceuticals Ag | Antibodies specific for claudin 6 (cldn6) |
| EP2366709A1 (en) * | 2010-03-16 | 2011-09-21 | BioNTech AG | Tumor vaccination involving a humoral immune response against self-proteins |
| AU2011229518B2 (en) | 2010-03-16 | 2015-09-24 | Biontech Protein Therapeutics Gmbh | Tumor vaccination involving a humoral immune response against self-proteins |
| EP2404936A1 (en) | 2010-07-06 | 2012-01-11 | Ganymed Pharmaceuticals AG | Cancer therapy using CLDN6 target-directed antibodies in vivo |
| JP2013537415A (ja) | 2010-08-03 | 2013-10-03 | アッヴィ・インコーポレイテッド | 二重可変ドメイン免疫グロブリンおよびその使用 |
| CA2809433A1 (en) | 2010-08-26 | 2012-03-01 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| CA2826563C (en) * | 2011-02-07 | 2020-10-20 | Paul Kussie | Methods and systems for treating eclampsia and pre-eclampsia |
| AU2012249454B2 (en) * | 2011-04-29 | 2016-03-24 | Apexigen, Inc. | Anti-CD40 antibodies and methods of use |
| KR102072183B1 (ko) | 2011-05-13 | 2020-02-03 | 가니메드 파마슈티칼스 게엠베하 | 클라우딘 6을 발현하는 암 치료용 항체 |
| US9120870B2 (en) | 2011-12-30 | 2015-09-01 | Abbvie Inc. | Dual specific binding proteins directed against IL-13 and IL-17 |
| WO2013167153A1 (en) * | 2012-05-09 | 2013-11-14 | Ganymed Pharmaceuticals Ag | Antibodies useful in cancer diagnosis |
| RS56187B1 (sr) * | 2012-05-23 | 2017-11-30 | Ganymed Pharmaceuticals Gmbh | Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera |
| WO2013174403A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| EP3725810B1 (en) | 2012-05-23 | 2022-07-06 | Astellas Pharma Inc. | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2013174404A1 (en) * | 2012-05-23 | 2013-11-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| BR112015009961B1 (pt) | 2012-11-01 | 2020-10-20 | Abbvie Inc. | proteína de ligação capaz de se ligar a dll4 e vegf, bem como composição que a compreende como composição que a compreende |
| US10093736B2 (en) * | 2012-11-13 | 2018-10-09 | Biontech Ag | Agents for treatment of claudin expressing cancer diseases |
| RS63738B1 (sr) * | 2013-02-20 | 2022-12-30 | Astellas Pharma Inc | Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera |
| WO2014127785A1 (en) * | 2013-02-20 | 2014-08-28 | Ganymed Pharmaceuticals Ag | Combination therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2014144280A2 (en) | 2013-03-15 | 2014-09-18 | Abbvie Inc. | DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17 |
| WO2014146672A1 (en) * | 2013-03-18 | 2014-09-25 | Ganymed Pharmaceuticals Ag | Therapy involving antibodies against claudin 18.2 for treatment of cancer |
| WO2015014376A1 (en) | 2013-07-31 | 2015-02-05 | Biontech Ag | Diagnosis and therapy of cancer involving cancer stem cells |
| WO2016094881A2 (en) | 2014-12-11 | 2016-06-16 | Abbvie Inc. | Lrp-8 binding proteins |
| WO2016165762A1 (en) * | 2015-04-15 | 2016-10-20 | Ganymed Pharmaceuticals Ag | Drug conjugates comprising antibodies against claudin 18.2 |
| WO2016180468A1 (en) * | 2015-05-11 | 2016-11-17 | Biontech Cell & Gene Therapies Gmbh | Claudin-18.2-specific immunoreceptors and t cell epitopes |
| TW201710286A (zh) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白 |
| EP3538141A4 (en) * | 2016-11-10 | 2020-07-15 | Merck Sharp & Dohme Corp. | ILT3 LIGAND |
| WO2018148595A1 (en) * | 2017-02-10 | 2018-08-16 | Washington University | Antibodies to tip1 and methods of use thereof |
| US20180298094A1 (en) * | 2017-04-17 | 2018-10-18 | Ksl Biomedical Llc | Monoclonal antibodies targeted to human taxilin alpha and methods for use of same |
| US11365249B2 (en) * | 2017-04-18 | 2022-06-21 | Good T Cells, Inc. | Binding molecule specific for Lrig-1 protein and use thereof |
| CN107779500A (zh) * | 2017-10-25 | 2018-03-09 | 上海药明生物技术有限公司 | 一种快速获取大鼠杂交瘤细胞单克隆抗体序列的测序方法及引物序列 |
| CN111836644B (zh) | 2018-03-08 | 2024-07-23 | 凡恩世制药(北京)有限公司 | 抗密蛋白18.2抗体及其用途 |
| EP3765502B1 (en) * | 2018-03-13 | 2024-08-07 | Tusk Therapeutics Ltd | Anti-cd25 for tumour specific cell depletion |
| EP3765522A4 (en) * | 2018-03-14 | 2022-05-18 | Beijing Xuanyi Pharmasciences Co., Ltd. | ANTI-CLAUDIN 18.2 ANTIBODIES |
| CN110862454B (zh) * | 2018-08-27 | 2022-12-30 | 南京圣和药业股份有限公司 | 一种抗Claudin18_2抗体及其应用 |
| US20210380680A1 (en) * | 2018-12-07 | 2021-12-09 | ZLlP HOLDING LIMITED | Anti-claudin antibodies and uses thereof |
| EP3904386A4 (en) * | 2018-12-28 | 2022-09-07 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | ANTIBODIES AND USE THEREOF |
| WO2020135674A1 (en) * | 2018-12-28 | 2020-07-02 | Nanjingjinsirui Science & Technology Biology Corp. | Claudin18.2 binding moieties and uses thereof |
| CN116333141A (zh) * | 2019-01-15 | 2023-06-27 | 浙江道尔生物科技有限公司 | 抗cld18a2纳米抗体及其应用 |
| CN109762067B (zh) * | 2019-01-17 | 2020-02-28 | 北京天广实生物技术股份有限公司 | 结合人Claudin 18.2的抗体及其用途 |
| CN113645996B (zh) * | 2019-02-01 | 2024-04-02 | 新石生物制药有限公司 | 抗claudin 18抗体及其使用方法 |
| MX2021011489A (es) * | 2019-04-01 | 2021-10-22 | Jiangsu Hengrui Medicine Co | Anticuerpo anti-claudina 18.2 y utilizacion del mismo. |
| CN111978402B (zh) * | 2019-05-24 | 2022-06-28 | 三优生物医药(上海)有限公司 | 新型cldn18.2结合分子 |
| TW202108627A (zh) * | 2019-05-24 | 2021-03-01 | 大陸商三優生物醫藥（上海）有限公司 | 新型cldn18.2結合分子 |
| WO2021011885A1 (en) | 2019-07-17 | 2021-01-21 | The Regents Of The University Of California | Claudin18 antibodies and methods of treating cancer |
| CA3149406A1 (en) * | 2019-08-20 | 2021-02-25 | Xueming Qian | Novel anti-cldn18.2 antibodies |
| CN112574307B (zh) * | 2019-09-29 | 2023-11-28 | 迈威(上海)生物科技股份有限公司 | 抗人Claudin18.2抗体及其应用 |
| WO2021111003A1 (en) | 2019-12-06 | 2021-06-10 | SOTIO a.s. | Humanized cldn18.2 antibodies |
| AU2020410998A1 (en) | 2019-12-23 | 2022-06-16 | Sotio Biotech A.S. | Tumor-specific Claudin 18.2 antibodies |
| JP7543411B2 (ja) * | 2020-01-03 | 2024-09-02 | クレージュ メディカル カンパニー，リミテッド | 抗クロ―ディン１８．２の抗体及びその使用 |
| KR20220161316A (ko) | 2020-03-30 | 2022-12-06 | 비온테크 에스이 | Claudin-18.2를 표적화하는 rna 조성물 |
| CN113493515B (zh) * | 2020-04-02 | 2023-03-28 | 广东菲鹏制药股份有限公司 | 抗cldn18a2的抗体以及治疗肿瘤的药物 |
| WO2021228141A1 (zh) * | 2020-05-15 | 2021-11-18 | 四川科伦博泰生物医药股份有限公司 | 抗体药物缀合物及其制备方法和用途 |
| CN111808194B (zh) * | 2020-07-13 | 2021-04-20 | 北京凯因科技股份有限公司 | 一种结合密蛋白的用于治疗癌症的人源化抗体 |
| WO2022011531A1 (zh) * | 2020-07-14 | 2022-01-20 | 浙江道尔生物科技有限公司 | 一种抗cld18a2的单域抗体 |
| WO2022122709A1 (en) | 2020-12-07 | 2022-06-16 | Sotio Biotech A.S. | Antibody-drug conjugates based on humanized cldn18.2 antibodies |
| US20240043529A1 (en) * | 2020-12-22 | 2024-02-08 | Eutropics Pharmaceuticals, Inc. | Methods and compositions related to bcl2 and bim heterodimer antibodies |
| CA3199830A1 (en) | 2020-12-23 | 2022-06-30 | Lukas BAMMERT | Tumor-specific claudin 18.2 antibody-drug conjugates |
| WO2023161457A1 (en) | 2022-02-27 | 2023-08-31 | Evobright Gmbh | Bispecific antibodies against cd277 and a tumor-antigen |
| CN114836388A (zh) * | 2022-06-07 | 2022-08-02 | 江苏亲科生物研究中心有限公司 | Claudin18.2单克隆抗体及其制备方法和用途 |
| WO2024074634A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
| WO2024074211A1 (en) | 2022-10-06 | 2024-04-11 | BioNTech SE | Rna compositions targeting claudin-18.2 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
| US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
| US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
| US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
| US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
| US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
| US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4954617A (en) | 1986-07-07 | 1990-09-04 | Trustees Of Dartmouth College | Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes |
| US4881175A (en) | 1986-09-02 | 1989-11-14 | Genex Corporation | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| US5013653A (en) | 1987-03-20 | 1991-05-07 | Creative Biomolecules, Inc. | Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| WO1991009974A1 (en) | 1989-12-27 | 1991-07-11 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Diagnostic probe for detecting human stomach cancer |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| IL154751A0 (en) | 2000-08-03 | 2003-10-31 | Humanized antibodies, recombination vectors, transgenic vectors and methods for the preparation of humanized antibodies from transgenic animals | |
| GB0020685D0 (en) * | 2000-08-22 | 2000-10-11 | Novartis Ag | Organic compounds |
| EP1916303B1 (en) | 2000-11-30 | 2013-02-27 | Medarex, Inc. | Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| KR101228124B1 (ko) * | 2002-06-14 | 2013-01-31 | 이뮤노메딕스, 인코오포레이티드 | 단클론 항체 ｐａｍ4 및 췌장암의 진단 및 치료를 위한이들의 용도 |
| EP2364996B1 (en) * | 2002-09-27 | 2016-11-09 | Xencor Inc. | Optimized FC variants and methods for their generation |
| PL218660B1 (pl) | 2002-10-17 | 2015-01-30 | Genmab As | Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie |
| DE10254601A1 (de) * | 2002-11-22 | 2004-06-03 | Ganymed Pharmaceuticals Ag | Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung |
| US20050255041A1 (en) | 2004-05-13 | 2005-11-17 | Arius Research, Inc. | Cancerous disease modifying antibodies |
| EP1954272A2 (en) * | 2005-10-31 | 2008-08-13 | Bayer Pharmaceuticals Corporation | Treatment of cancer with sorafenib |
| EP1790664A1 (en) * | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
-
2007
- 2007-05-29 EP EP07010622A patent/EP1997832A1/en not_active Withdrawn
-
2008
- 2008-05-27 WO PCT/EP2008/004197 patent/WO2008145338A2/en active Application Filing
- 2008-05-27 NZ NZ581365A patent/NZ581365A/en unknown
- 2008-05-27 KR KR1020157003504A patent/KR101693365B1/ko active IP Right Grant
- 2008-05-27 DK DK18168460.6T patent/DK3401334T5/da active
- 2008-05-27 KR KR1020097024616A patent/KR101585990B1/ko active IP Right Grant
- 2008-05-27 ES ES18168460T patent/ES2940775T3/es active Active
- 2008-05-27 JP JP2010509723A patent/JP5816431B2/ja active Active
- 2008-05-27 PT PT181684606T patent/PT3401334T/pt unknown
- 2008-05-27 CN CN2008800180365A patent/CN101687929B/zh active Active
- 2008-05-27 HU HUE18168460A patent/HUE061795T2/hu unknown
- 2008-05-27 LT LTEP18168460.6T patent/LT3401334T/lt unknown
- 2008-05-27 HR HRP20230282TT patent/HRP20230282T3/hr unknown
- 2008-05-27 SG SG2012063251A patent/SG183773A1/en unknown
- 2008-05-27 KR KR1020167036984A patent/KR101751965B1/ko active IP Right Grant
- 2008-05-27 RS RS20230214A patent/RS64065B1/sr unknown
- 2008-05-27 CA CA2687206A patent/CA2687206C/en active Active
- 2008-05-27 CN CN201310574213.0A patent/CN103694353B/zh active Active
- 2008-05-27 RU RU2015149617A patent/RU2682285C2/ru active
- 2008-05-27 SI SI200832208T patent/SI3401334T1/sl unknown
- 2008-05-27 MX MX2009012906A patent/MX2009012906A/es active IP Right Grant
- 2008-05-27 FI FIEP18168460.6T patent/FI3401334T3/fi active
- 2008-05-27 US US12/601,488 patent/US8425902B2/en active Active
- 2008-05-27 PL PL18168460.6T patent/PL3401334T3/pl unknown
- 2008-05-27 BR BRPI0811907-4A2A patent/BRPI0811907A2/pt not_active Application Discontinuation
- 2008-05-27 EP EP23155995.6A patent/EP4242236A3/en active Pending
- 2008-05-27 EP EP18168460.6A patent/EP3401334B1/en active Active
- 2008-05-27 EP EP08758782.0A patent/EP2152754B8/en active Active
- 2008-05-27 ES ES08758782T patent/ES2675375T3/es active Active
- 2008-05-27 RU RU2009149205/10A patent/RU2571923C2/ru active
-
2009
- 2009-10-21 IL IL201666A patent/IL201666A/en active IP Right Grant
- 2009-11-02 ZA ZA2009/07675A patent/ZA200907675B/en unknown
-
2014
- 2014-07-24 JP JP2014150605A patent/JP5995919B2/ja active Active
-
2015
- 2015-05-07 IL IL238668A patent/IL238668A0/en unknown
- 2015-05-07 IL IL238667A patent/IL238667A0/en active IP Right Grant
-
2016
- 2016-08-23 JP JP2016162892A patent/JP6337053B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20230282T3 (hr) | Monoklonska antitijela protiv klaudina-18 za liječenje raka | |
| RU2445319C2 (ru) | Моноклональные антитела к клаудину-18 для лечения рака | |
| US20230192847A1 (en) | Tigit antibodies, encoding nucleic acids and methods of using said antibodies in vivo | |
| US20240343810A1 (en) | Multispecific antibodies for immuno-oncology | |
| US20210198363A1 (en) | Anti pd-1 antibodies | |
| HRP20191609T1 (hr) | Protein | |
| HRP20191341T1 (hr) | Protutijela koja vežu ljudski cgrp receptor | |
| CN107922494B (zh) | 抗pd-1抗体及其应用 | |
| HRP20180352T1 (hr) | Protutijela anti-fcrh5 | |
| JP2019503687A (ja) | 抗ｐｄ−ｌ１抗体およびその使用 | |
| HRP20171274T1 (hr) | U potpunosti ljudska antitijela specifična za cadm1 | |
| AU2017228470A1 (en) | Combination therapy with anti-CD73 antibodies | |
| JP2017511376A5 (hr) | ||
| JP2017149720A5 (hr) | ||
| JP2018509175A5 (hr) | ||
| CN118388646A (zh) | 抗pd-l1抗体 | |
| JP2017509643A5 (hr) | ||
| JP2015163068A5 (hr) | ||
| JP2009506791A5 (hr) | ||
| US20240010741A1 (en) | Agonistic cd40 antibodies | |
| JP2020515249A5 (hr) | ||
| WO2013188864A4 (en) | Anti-cd22 anti-idiotypic antibodies and uses thereof | |
| SI2125897T1 (en) | MONOCOLONIAL PROTITELES AGAINST GT 468 FOR CARRYING CANCER | |
| JP2019515683A5 (hr) | ||
| JP2020502198A (ja) | 癌免疫療法のための併用療法での多重特異性抗体 |